PROF. MUZAFFAR LATIF GILL

Clinical research has been my passion.I was able to learn the basic fundamentals of research during my training years in United States.I did master of science (M.S) in clinical research from school of public health, University of Minnesota USA. This training gave me very strong basics in research methodology.In the last 10 years I have been able to conduct more than 50 studies in the field of Gastroenterology and Hepatology. These studies are presented in national and international meetings and published in international peer review journals especially in United States and Europe.

International Publications

Clinical research has been my passion.I was able to learn the basic fundamentals of research during my training years in United States.I did master of science (M.S) in clinical research from school of public health, University of Minnesota USA. This training gave me very strong basics in research methodology.In the last 10 years I have been able to conduct more than 50 studies in the field of Gastroenterology and Hepatology. These studies are presented in national and international meetings and published in international peer review journals especially in United States and Europe.

  • Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol. 2018 Oct 4. doi: 10.1089/vim.2018.0022
  • Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Aziz H, Gil M L, Waheed Y, Adeeb U, Raza A, Bilal I, Athar M A Infection, Genetics and Evolution 11 (2011) 640–645
  • Analysis of Prognostic Factors For SVR to PEG Interferon alfa-2a plus Ribavirin in HCV Genotype 3 Infected Patients. Aziz H, Raza A, Waheed Y, Gill U, Gill ML. International journal of Infectious disease. 2012;16(8):e597-602.
  • Gill U, Aziz H, Gill ML. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. 2013 17(11):e1017-21.
  • Hafsa Aziz , Uzma Gill , Abida Raza , Muzaffar Lateef Gill . 2014. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients. Eur J Gastroenterol Hepatol. 26(5):538-43.
  • Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. 2015. Polymorphism ofthe IL28B gene (rs8099917, rs12979860)and virological response of Pakistani hepatitis C virus geno type 3 patients to pegylated interferon therapy. Int J Infect Dis. 30:91-7.
  • Aziz H, Aziz M, Gill ML. Analysis of Host and ViralRelated Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. Viral Immunol. 2018. 31(3):256-263. I F: 1.53
  • Evaluation of prognostic factors for peg-Interferon alpha-2b plus Ribavirin treatment for HCV infected patients in Pakistan. More Details
  • Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. More Details
  • Preditors of outcomes after biliary and pancreatic sphincterotomy for sphinctor of oddi dysfunction , Martin Freeman , Muzzaffar Gill , Carol Overby , Journal of clinical gastroenterology 2007 , Volume 41 , issue 1 , page 94-102.
  • Gill Muzaffar, Firdoos S, Sattar S, Ali y, treatment outcomes of hepC G3 patients with pegasays and ribavirin vs pegintron plus ribavirin . 17th asia pacific association of liver diseases conference march 27-30 kyoto japan.
  • Gill Muzaffar Firdoos S,Sattar S, TA Shah, treatment outcomes of hepC G3 patients with reduced dose of peginterferon and ribavirin asia pacific association of liver diseases conference march 27-30 kyoto jaopan
  • Gill Muzaffar, Firdoos s,Butt N, Amin A, Khokhar N, outcomes of treatment of HEP C g3 patients with thrice weekly standard interferon and ribavirin Asia pacific association of liver disease conference march 27-30 kyoto japan.
  • Gill Muzaffar,Firdoos S, N Khokhar, efficacy of peginterferon alfa 2a/ ribavirin treatment in hepC g3 relapsers with standard itterferon/ribavirin, Asia pacific association of liver disease conference march 27 -30 kyoto japan.
  • Gill Muzaffar,Firdoos S, Shah TA, Sattar s, outcomes of peginterferon alfa 2b / ribavirin treatment in HEP C g3 younger vs older patients. Asia pacific association of liver disease conference march 27 -30 kyoto japan.
  • Gill Muzaffar ,Firdoos S, N Butt, Khokhar N, Lonh term outcomes of HEP C G3 patients who had svrrr after 6 months of treatment with peg-intron and ribavirin. 4th international symposium on hepC 9-13th sep 2007 Glasgow Scotland.
  • Gill Muzaffar , Firdoos s,Butt N, Adeeb U, Shah TA, treatment outcomes of hepC genotype 3 patients with pegasays, ribavirin without rapid virological response. 4th international symposium on HEP C 9-13th sep 2007
  • Gill Muzaffar, Firdoos S, Sattar S, N Butt, N Khokhar, Outcomes of terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome. Gut 2007: (suppl III)
  • Gill Muzaffar, Firdoos S , Butt N , Adeeb U , Shah T.A,, Role of adjuvant therapy with erythropoietin and GCSF to improve sustained virological response in chronic hep C patients receiving peg intron and ribavirin .GUT 2007: 56( suppl III)
  • Gill Muzaffar , Firdoos S,N Khokhar ,S Sattar ,Treatment outcomes of Hep C Genotype 3 patients with pegasys and ribavirin without virological response Gut 2007:56(suppl111)
  • Khokhar N, Gill Muzaffar, triple regime therapy for chronic hepatitis C patients. Journal of gastro- Hepatol, December 2004.
  • Gill Muzaffar, Atiq M, Sattar S. Tauqir A.Shah, Psychological impact of hepatitis C diagnosis in Pakistani population, Journal of gastro- Hepatol, December 2004.
  • Gill Muzaffar, Atiq M, Sattar S, Nasir, Khokhar, treatment outcomes of chronic hepatitis C patients with normal ALT with Pegylated interferon journal gastro-Hepatol December 2004.
  • Gill Muzaffar, Khokhar N, Ali Yawar Alam, Lamuvidine treatment for chronic Hepatitis B, JCPSP 2005 Vol 15 (2) 78: 80
  • Gill Muzaffar, Atiq M, Sattar S, Physiological impact of HCV diagnosis Journal of Gastro Hepatol 2005, 11 200-205.
  • Gill Muzaffar, Atiq M, Khokhar N: Treatment outcomes with long acting Octreotide in Inoperable Hepatocellular Carcinoma. J Pak Medical Association, 500-503 JPMA 2005.
  • Khokhar N, Gill Muzaffar: Percutaneous Endoscopic Gastrostomy at Shifa. In press.
  • Khokhar N. Naz F, Gill Muzaffar, Mahmood N.: Prevalence of hepatitis C in patients with chronic renal failure. In press J Pak Med Assoc.
    Khokhar N, Gill Muzaffar: Achalasia dilatation without Fluoroscopy in press. JPMA.
  • Gill Muzaffar, Atiq M, Khokhar N: Treatment Outcomes of Pegylated Interferon Alpha-2a in combination with Ribavirin Versus Standard Interferon and Ribavirin in Chronic Hepatitis C Patients. In press, Journal of Gastro-Hepatol.
  • Gill Muzaffar, Khokhar N, Butt MB: Successful treatment of CHC with high doses Pegylated Interferon in viral resistant Hepatitis C patients. JCPSP September 2004.
  • Gill Muzaffar, Khokhar N: Outcomes of triple therapies for hepatitis C patients, Pakistani experience. Journal of Gastro-Hepatol December 2004.
  • Gill Muzaffar, Atiq M: Treatment outcomes of Hepatitis C patients with normal ALT. Journal of gastro- Hepatol, December 2004.
  • Gill Muzaffar, Khokhar N, Malik Gj. General Seroprevalence of hepatitis C and Hepatitis B virus infections in Pakistani population. JCPSP 2004; 14:534-538.
  • Gill Muzaffar, Atiq M, Sattar S, Khokhar N: Non-endoscopic parameters for the identification of esophageal varices in patients with cirrhosis: A cross-sectional study and literature review. J Pak Med Association 2004. 11, 575-577
  • Khokhar N, Gill Muzaffar: Gastrointestinal injury from NSAIDS. Rawal Medical Journal 2003:28; 22-24.
  • Atiq M, Gill Muzaffar, Khokhar N: Quality of life assessment in Pakistani patients with chronic liver disease J Pak Medical Assoc 2004; 54:113-115.
  • Atiq M, Gill Muzaffar, Khokhar N. Small bowel vascular insufficiency presenting as abdominal pain. Rawal Medical J 2004; 29:42-43.
  • Khokhar N, Gill Muzaffar: Serological profile of incidentally detected asymptomatic HBs Ag positive subjects (IDAHS) JPMA 2004; 14:16-18.
  • Khokhar N, Gill Muzaffar. Tropical Sprue in Pakistan. J Pak Medical Assoc 2004; 54:135.
  • Khokhar N, Aijazi I, Gill Muzaffar. Spectrum of Hepatocellular Carcinoma at Shifa International Hospital, Islamabad. J. Ayub Medical Coll Abbottabad 2003; 15:1-4
  • Khokhar N, Gill Muzaffar, Khan MM. Esophageal strictures in a tertiary care center. J Coll Physicians Surg Pak 2003; 14:553-555
    Gill Muzaffar, MD, Martin Freeman, MD. Incidence of duodenal ulcer in Guaic negative nasogastric aspirates patients. Gastroenterology 1999, 22. 1250 – 1256.
  • Samuel Ho, MD, Gill Muzaffar, MD. Incidence of psychiatric problems in Hepatitis C patients treated with Interferon / Ribavirin. Hepatology 1998; 28: 1260 – 1268.
  • Gill Muzaffar, JL Anderton, Alp Notghi. Long-acting calcium channel blocker in renal impairment patients, Nephrology dialysis and transplantation. 7, 701-708, 1994.
  • Anderton JL, Gill Muzaffar, Notghi A. Renal hemodynamic effects of bunazosin retard and Prazosin in mild to moderately hypertensive patients with normal or moderately impaired renal function. Nephrology, Dialysis and Transplantation 9:607 – 612, 1994.
  • Gill Muzaffar, Anderton JL, Erythroetin-induced hypertension without raising hematocrit. Nephrology, Dialysis and Transplantation 3:1264-1266, 1993.
Book Consultation
Leading Gastroenterologist & Hepatologist: Dedicated to your digestive health and liver wellness."

Working Hours

Monday: 
11am - 6pm
Tuesday: 
11am - 6pm
Wednesday: 
11am - 6pm
Thursday: 
11am - 6pm
Friday:
11am - 6pm
Saturday:
11am - 6pm

Copyright © 2024 Prof Muzaffar Latif Gill. All rights reserved. Powered By AKITS

Disclaimer: This website’s content is for educational purposes only and should not replace professional medical advice or treatment.
We are not liable for the accuracy, completeness, or timeliness of the information, nor for any actions taken based on it.

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram